Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yimaikang Capsules (益脉康胶囊) is an approved Traditional Chinese Medicine (TCM) herbal formulation developed and manufactured by Xishuangbanna Rainforest Pharmaceutical Co., Ltd. The active ingredient is an extract of *Erigeron breviscapus* (Dengzhan Xixin). It is primarily indicated for the treatment of cerebrovascular diseases, including ischemic stroke and paralysis following hemorrhagic stroke. The drug functions by promoting blood circulation and resolving blood stasis, which enhances cerebral blood flow and improves microcirculation. Additionally, it is used for retinal vein occlusion, coronary heart disease, and certain inflammatory vascular or rheumatic conditions. It is administered orally, typically as one capsule three times daily.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yimaikang Capsules.